martes, 31 de marzo de 2020

Chinese regulator scolds a U.S. company for drug-manufacturing problems

Chinese regulator scolds a U.S. company for drug-manufacturing problems

Cancer Briefing



STAT Plus: The tables are turned: Chinese regulator scolds a U.S. company for drug-manufacturing problems

By ED SILVERMAN


IMAGINECHINA VIA AP
“As the marketing agent for Abraxane in China, we are extremely disappointed by this interruption in drug supply,” said the BeiGene chief executive officer.

No hay comentarios:

Publicar un comentario